Listed

Oric Pharmaceuticals, Inc.

ORICNasdaqCIK 1796280HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Operating income−$45.3m, Q2 FY2026
Net income−$41.5m, Q2 FY2026
Oric Pharmaceuticals, Inc., income statement, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Research and development$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Operating income$m(28.7)Operating income, Q3 FY2023, three months to 2023-09-30−$28.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-12, accession 0000950170-24-125471.Report this figure(31.4)Operating income, Q4 FY2023, three months to 2023-12-31−$31.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-02-18, accession 0000950170-25-022273. Derived: 12-month figure less the 9-month figure.Report this figure(29.0)Operating income, Q1 FY2024, three months to 2024-03-31−$29.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-05, accession 0000950170-25-063564.Report this figure(36.0)Operating income, Q2 FY2024, three months to 2024-06-30−$36.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-12, accession 0000950170-25-107359.Report this figure(38.3)Operating income, Q3 FY2024, three months to 2024-09-30−$38.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-13, accession 0001193125-25-280234.Report this figure(39.6)Operating income, Q4 FY2024, three months to 2024-12-31−$39.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-23, accession 0001193125-26-064005. Derived: 12-month figure less the 9-month figure.Report this figure(32.7)Operating income, Q1 FY2025, three months to 2025-03-31−$32.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-04, accession 0001193125-26-204047.Report this figure(39.1)Operating income, Q2 FY2025, three months to 2025-06-30−$39.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-03, accession 0001193125-26-330631.Report this figure(36.7)Operating income, Q3 FY2025, three months to 2025-09-30−$36.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-13, accession 0001193125-25-280234.Report this figure(34.6)Operating income, Q4 FY2025, three months to 2025-12-31−$34.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-23, accession 0001193125-26-064005. Derived: 12-month figure less the 9-month figure.Report this figure(39.6)Operating income, Q1 FY2026, three months to 2026-03-31−$39.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-04, accession 0001193125-26-204047.Report this figure(45.3)Operating income, Q2 FY2026, three months to 2026-06-30−$45.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-03, accession 0001193125-26-330631.Report this figure
Income tax$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Net income$m(25.5)Net income, Q3 FY2023, three months to 2023-09-30−$25.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-12, accession 0000950170-24-125471.Report this figure(28.3)Net income, Q4 FY2023, three months to 2023-12-31−$28.3m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-02-18, accession 0000950170-25-022273. Derived: 12-month figure less the 9-month figure.Report this figure(25.0)Net income, Q1 FY2024, three months to 2024-03-31−$25.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-05-05, accession 0000950170-25-063564.Report this figure(32.0)Net income, Q2 FY2024, three months to 2024-06-30−$32.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-08-12, accession 0000950170-25-107359.Report this figure(34.6)Net income, Q3 FY2024, three months to 2024-09-30−$34.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-13, accession 0001193125-25-280234.Report this figure(36.3)Net income, Q4 FY2024, three months to 2024-12-31−$36.3m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-23, accession 0001193125-26-064005. Derived: 12-month figure less the 9-month figure.Report this figure(30.0)Net income, Q1 FY2025, three months to 2025-03-31−$30.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-04, accession 0001193125-26-204047.Report this figure(36.4)Net income, Q2 FY2025, three months to 2025-06-30−$36.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-03, accession 0001193125-26-330631.Report this figure(32.6)Net income, Q3 FY2025, three months to 2025-09-30−$32.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-13, accession 0001193125-25-280234.Report this figure(30.5)Net income, Q4 FY2025, three months to 2025-12-31−$30.5m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-23, accession 0001193125-26-064005. Derived: 12-month figure less the 9-month figure.Report this figure(35.8)Net income, Q1 FY2026, three months to 2026-03-31−$35.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-04, accession 0001193125-26-204047.Report this figure(41.5)Net income, Q2 FY2026, three months to 2026-06-30−$41.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-03, accession 0001193125-26-330631.Report this figure
Diluted EPS$ per share(0.44)Diluted EPS, Q3 FY2023, three months to 2023-09-30−$0.44 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-12, accession 0000950170-24-125471.Report this figurenot reported(0.37)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$0.37 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-05, accession 0000950170-25-063564.Report this figure(0.45)Diluted EPS, Q2 FY2024, three months to 2024-06-30−$0.45 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-12, accession 0000950170-25-107359.Report this figure(0.49)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.49 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-13, accession 0001193125-25-280234.Report this figurenot reported(0.42)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.42 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-04, accession 0001193125-26-204047.Report this figure(0.47)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.47 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-03, accession 0001193125-26-330631.Report this figure(0.33)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.33 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-13, accession 0001193125-25-280234.Report this figurenot reported(0.34)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.34 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-04, accession 0001193125-26-204047.Report this figure(0.38)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.38 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-03, accession 0001193125-26-330631.Report this figure
Basic EPS$ per share(0.44)Basic EPS, Q3 FY2023, three months to 2023-09-30−$0.44 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-12, accession 0000950170-24-125471.Report this figurenot reported(0.37)Basic EPS, Q1 FY2024, three months to 2024-03-31−$0.37 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-05, accession 0000950170-25-063564.Report this figure(0.45)Basic EPS, Q2 FY2024, three months to 2024-06-30−$0.45 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-12, accession 0000950170-25-107359.Report this figure(0.49)Basic EPS, Q3 FY2024, three months to 2024-09-30−$0.49 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-13, accession 0001193125-25-280234.Report this figurenot reported(0.42)Basic EPS, Q1 FY2025, three months to 2025-03-31−$0.42 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-04, accession 0001193125-26-204047.Report this figure(0.47)Basic EPS, Q2 FY2025, three months to 2025-06-30−$0.47 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-03, accession 0001193125-26-330631.Report this figure(0.33)Basic EPS, Q3 FY2025, three months to 2025-09-30−$0.33 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-13, accession 0001193125-25-280234.Report this figurenot reported(0.34)Basic EPS, Q1 FY2026, three months to 2026-03-31−$0.34 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-04, accession 0001193125-26-204047.Report this figure(0.38)Basic EPS, Q2 FY2026, three months to 2026-06-30−$0.38 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-03, accession 0001193125-26-330631.Report this figure

Balance sheet

Cash and equivalents$37.5m, Q2 FY2026
Shareholders' equity$381.3m, Q2 FY2026
Oric Pharmaceuticals, Inc., balance sheet, quarterly
Line itemUnitQ3 FY20232023-09-30FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$m26.2Cash and equivalents, Q3 FY2023, at 2023-09-30$26.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-12, accession 0000950170-24-125471.Report this figure23.4Cash and equivalents, FY2023, at 2023-12-31$23.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2025-02-18, accession 0000950170-25-022273.Report this figure56.4Cash and equivalents, Q1 FY2024, at 2024-03-31$56.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-05, accession 0000950170-25-063564.Report this figure49.8Cash and equivalents, Q2 FY2024, at 2024-06-30$49.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-12, accession 0000950170-25-107359.Report this figure44.2Cash and equivalents, Q3 FY2024, at 2024-09-30$44.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-13, accession 0001193125-25-280234.Report this figure59.4Cash and equivalents, FY2024, at 2024-12-31$59.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-02-23, accession 0001193125-26-064005.Report this figure49.3Cash and equivalents, Q1 FY2025, at 2025-03-31$49.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-04, accession 0001193125-26-204047.Report this figure75.9Cash and equivalents, Q2 FY2025, at 2025-06-30$75.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-03, accession 0001193125-26-330631.Report this figure49.7Cash and equivalents, Q3 FY2025, at 2025-09-30$49.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-13, accession 0001193125-25-280234.Report this figure45.7Cash and equivalents, FY2025, at 2025-12-31$45.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-03, accession 0001193125-26-330631.Report this figure56.4Cash and equivalents, Q1 FY2026, at 2026-03-31$56.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-04, accession 0001193125-26-204047.Report this figure37.5Cash and equivalents, Q2 FY2026, at 2026-06-30$37.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-03, accession 0001193125-26-330631.Report this figure
Current assets$m232Current assets, Q3 FY2023, at 2023-09-30$232.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-11-06, accession 0000950170-23-059415.Report this figure213Current assets, FY2023, at 2023-12-31$212.6m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-02-18, accession 0000950170-25-022273.Report this figure324Current assets, Q1 FY2024, at 2024-03-31$324.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-06, accession 0000950170-24-053582.Report this figure295Current assets, Q2 FY2024, at 2024-06-30$294.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-12, accession 0000950170-24-095467.Report this figure279Current assets, Q3 FY2024, at 2024-09-30$279.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-12, accession 0000950170-24-125471.Report this figure262Current assets, FY2024, at 2024-12-31$262.3m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-02-23, accession 0001193125-26-064005.Report this figure211Current assets, Q1 FY2025, at 2025-03-31$211.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-05, accession 0000950170-25-063564.Report this figure291Current assets, Q2 FY2025, at 2025-06-30$291.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-12, accession 0000950170-25-107359.Report this figure296Current assets, Q3 FY2025, at 2025-09-30$295.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-13, accession 0001193125-25-280234.Report this figure288Current assets, FY2025, at 2025-12-31$288.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-03, accession 0001193125-26-330631.Report this figure290Current assets, Q1 FY2026, at 2026-03-31$290.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-04, accession 0001193125-26-204047.Report this figure274Current assets, Q2 FY2026, at 2026-06-30$273.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-03, accession 0001193125-26-330631.Report this figure
Total assets$m274Total assets, Q3 FY2023, at 2023-09-30$274.3m. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-06, accession 0000950170-23-059415.Report this figure252Total assets, FY2023, at 2023-12-31$252.0m. XBRL concept us-gaap:Assets. 10-K filed 2025-02-18, accession 0000950170-25-022273.Report this figure351Total assets, Q1 FY2024, at 2024-03-31$350.8m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-06, accession 0000950170-24-053582.Report this figure329Total assets, Q2 FY2024, at 2024-06-30$328.9m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-12, accession 0000950170-24-095467.Report this figure302Total assets, Q3 FY2024, at 2024-09-30$302.1m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-12, accession 0000950170-24-125471.Report this figure274Total assets, FY2024, at 2024-12-31$274.1m. XBRL concept us-gaap:Assets. 10-K filed 2026-02-23, accession 0001193125-26-064005.Report this figure243Total assets, Q1 FY2025, at 2025-03-31$242.9m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-05, accession 0000950170-25-063564.Report this figure347Total assets, Q2 FY2025, at 2025-06-30$346.9m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-12, accession 0000950170-25-107359.Report this figure431Total assets, Q3 FY2025, at 2025-09-30$431.2m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-13, accession 0001193125-25-280234.Report this figure409Total assets, FY2025, at 2025-12-31$408.9m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-03, accession 0001193125-26-330631.Report this figure437Total assets, Q1 FY2026, at 2026-03-31$436.8m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-04, accession 0001193125-26-204047.Report this figure405Total assets, Q2 FY2026, at 2026-06-30$404.7m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-03, accession 0001193125-26-330631.Report this figure
Current liabilities$m18.9Current liabilities, Q3 FY2023, at 2023-09-30$18.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-11-06, accession 0000950170-23-059415.Report this figure20.5Current liabilities, FY2023, at 2023-12-31$20.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-02-18, accession 0000950170-25-022273.Report this figure15.2Current liabilities, Q1 FY2024, at 2024-03-31$15.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-06, accession 0000950170-24-053582.Report this figure19.5Current liabilities, Q2 FY2024, at 2024-06-30$19.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-12, accession 0000950170-24-095467.Report this figure21.2Current liabilities, Q3 FY2024, at 2024-09-30$21.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-12, accession 0000950170-24-125471.Report this figure24.8Current liabilities, FY2024, at 2024-12-31$24.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-02-23, accession 0001193125-26-064005.Report this figure17.6Current liabilities, Q1 FY2025, at 2025-03-31$17.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-05, accession 0000950170-25-063564.Report this figure18.1Current liabilities, Q2 FY2025, at 2025-06-30$18.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-12, accession 0000950170-25-107359.Report this figure20.2Current liabilities, Q3 FY2025, at 2025-09-30$20.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-13, accession 0001193125-25-280234.Report this figure20.4Current liabilities, FY2025, at 2025-12-31$20.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-03, accession 0001193125-26-330631.Report this figure17.8Current liabilities, Q1 FY2026, at 2026-03-31$17.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-04, accession 0001193125-26-204047.Report this figure20.8Current liabilities, Q2 FY2026, at 2026-06-30$20.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-03, accession 0001193125-26-330631.Report this figure
Total liabilities$m26.9Total liabilities, Q3 FY2023, at 2023-09-30$26.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-11-06, accession 0000950170-23-059415.Report this figure27.9Total liabilities, FY2023, at 2023-12-31$27.9m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-02-18, accession 0000950170-25-022273.Report this figure22.1Total liabilities, Q1 FY2024, at 2024-03-31$22.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-06, accession 0000950170-24-053582.Report this figure26.5Total liabilities, Q2 FY2024, at 2024-06-30$26.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-12, accession 0000950170-24-095467.Report this figure28.1Total liabilities, Q3 FY2024, at 2024-09-30$28.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-12, accession 0000950170-24-125471.Report this figure31.0Total liabilities, FY2024, at 2024-12-31$31.0m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-02-23, accession 0001193125-26-064005.Report this figure23.1Total liabilities, Q1 FY2025, at 2025-03-31$23.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-05, accession 0000950170-25-063564.Report this figure22.9Total liabilities, Q2 FY2025, at 2025-06-30$22.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-12, accession 0000950170-25-107359.Report this figure24.3Total liabilities, Q3 FY2025, at 2025-09-30$24.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-13, accession 0001193125-25-280234.Report this figure24.5Total liabilities, FY2025, at 2025-12-31$24.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-03, accession 0001193125-26-330631.Report this figure21.2Total liabilities, Q1 FY2026, at 2026-03-31$21.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-04, accession 0001193125-26-204047.Report this figure23.4Total liabilities, Q2 FY2026, at 2026-06-30$23.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-03, accession 0001193125-26-330631.Report this figure
Long-term debt$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Shareholders' equity$m247Shareholders' equity, Q3 FY2023, at 2023-09-30$247.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-12, accession 0000950170-24-125471.Report this figure224Shareholders' equity, FY2023, at 2023-12-31$224.1m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-02-23, accession 0001193125-26-064005.Report this figure329Shareholders' equity, Q1 FY2024, at 2024-03-31$328.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-13, accession 0001193125-25-280234.Report this figure302Shareholders' equity, Q2 FY2024, at 2024-06-30$302.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-13, accession 0001193125-25-280234.Report this figure274Shareholders' equity, Q3 FY2024, at 2024-09-30$274.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-13, accession 0001193125-25-280234.Report this figure243Shareholders' equity, FY2024, at 2024-12-31$243.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-03, accession 0001193125-26-330631.Report this figure220Shareholders' equity, Q1 FY2025, at 2025-03-31$219.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-03, accession 0001193125-26-330631.Report this figure324Shareholders' equity, Q2 FY2025, at 2025-06-30$324.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-03, accession 0001193125-26-330631.Report this figure407Shareholders' equity, Q3 FY2025, at 2025-09-30$406.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-13, accession 0001193125-25-280234.Report this figure384Shareholders' equity, FY2025, at 2025-12-31$384.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-03, accession 0001193125-26-330631.Report this figure416Shareholders' equity, Q1 FY2026, at 2026-03-31$415.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-03, accession 0001193125-26-330631.Report this figure381Shareholders' equity, Q2 FY2026, at 2026-06-30$381.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-03, accession 0001193125-26-330631.Report this figure

Cash flow

Operating cash flow−$31.6m, Q2 FY2026
Capital expenditure$356.0k, Q2 FY2026
Oric Pharmaceuticals, Inc., cash flow, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$m(19.6)Operating cash flow, Q3 FY2023, three months to 2023-09-30−$19.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-12, accession 0000950170-24-125471. Derived: 9-month figure less the 6-month figure.Report this figure(24.3)Operating cash flow, Q4 FY2023, three months to 2023-12-31−$24.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-02-18, accession 0000950170-25-022273. Derived: 12-month figure less the 9-month figure.Report this figure(30.2)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$30.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-05, accession 0000950170-25-063564.Report this figure(25.6)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$25.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-12, accession 0000950170-25-107359. Derived: 6-month figure less the 3-month figure.Report this figure(28.8)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$28.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-13, accession 0001193125-25-280234. Derived: 9-month figure less the 6-month figure.Report this figure(28.1)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$28.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-23, accession 0001193125-26-064005. Derived: 12-month figure less the 9-month figure.Report this figure(32.5)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$32.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-04, accession 0001193125-26-204047.Report this figure(30.8)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$30.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-03, accession 0001193125-26-330631. Derived: 6-month figure less the 3-month figure.Report this figure(25.1)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$25.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-13, accession 0001193125-25-280234. Derived: 9-month figure less the 6-month figure.Report this figure(22.5)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$22.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-23, accession 0001193125-26-064005. Derived: 12-month figure less the 9-month figure.Report this figure(32.4)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$32.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-04, accession 0001193125-26-204047.Report this figure(31.6)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$31.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-03, accession 0001193125-26-330631. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$m0.1Capital expenditure, Q3 FY2023, three months to 2023-09-30$77.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2024-11-12, accession 0000950170-24-125471. Derived: 9-month figure less the 6-month figure.Report this figure0.1Capital expenditure, Q4 FY2023, three months to 2023-12-31$57.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-02-18, accession 0000950170-25-022273. Derived: 12-month figure less the 9-month figure.Report this figure0.2Capital expenditure, Q1 FY2024, three months to 2024-03-31$218.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-05-05, accession 0000950170-25-063564.Report this figure0.3Capital expenditure, Q2 FY2024, three months to 2024-06-30$333.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-08-12, accession 0000950170-25-107359. Derived: 6-month figure less the 3-month figure.Report this figure0.4Capital expenditure, Q3 FY2024, three months to 2024-09-30$418.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-13, accession 0001193125-25-280234. Derived: 9-month figure less the 6-month figure.Report this figure0.2Capital expenditure, Q4 FY2024, three months to 2024-12-31$219.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-23, accession 0001193125-26-064005. Derived: 12-month figure less the 9-month figure.Report this figure0.4Capital expenditure, Q1 FY2025, three months to 2025-03-31$387.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-04, accession 0001193125-26-204047.Report this figure0.1Capital expenditure, Q2 FY2025, three months to 2025-06-30$63.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-03, accession 0001193125-26-330631. Derived: 6-month figure less the 3-month figure.Report this figure0.0Capital expenditure, Q3 FY2025, three months to 2025-09-30$35.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-13, accession 0001193125-25-280234. Derived: 9-month figure less the 6-month figure.Report this figure0.2Capital expenditure, Q4 FY2025, three months to 2025-12-31$227.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-23, accession 0001193125-26-064005. Derived: 12-month figure less the 9-month figure.Report this figure0.0Capital expenditure, Q1 FY2026, three months to 2026-03-31$2.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-04, accession 0001193125-26-204047.Report this figure0.4Capital expenditure, Q2 FY2026, three months to 2026-06-30$356.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-03, accession 0001193125-26-330631. Derived: 6-month figure less the 3-month figure.Report this figure

Shares

Diluted shares (weighted)108.01m, Q2 FY2026
Oric Pharmaceuticals, Inc., shares, quarterly
Line itemUnitQ3 FY20222022-09-30Q1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares39.6Diluted shares (weighted), Q3 FY2022, three months to 2022-09-3039,575,660 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-11-06, accession 0000950170-23-059415.Report this figure45.1Diluted shares (weighted), Q1 FY2023, three months to 2023-03-3145,090,166 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-05-06, accession 0000950170-24-053582.Report this figure45.7Diluted shares (weighted), Q2 FY2023, three months to 2023-06-3045,654,208 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-12, accession 0000950170-24-095467.Report this figure57.4Diluted shares (weighted), Q3 FY2023, three months to 2023-09-3057,402,226 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-11-12, accession 0000950170-24-125471.Report this figure67.3Diluted shares (weighted), Q1 FY2024, three months to 2024-03-3167,349,551 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-05, accession 0000950170-25-063564.Report this figure70.3Diluted shares (weighted), Q2 FY2024, three months to 2024-06-3070,348,414 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-12, accession 0000950170-25-107359.Report this figure70.5Diluted shares (weighted), Q3 FY2024, three months to 2024-09-3070,542,684 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-13, accession 0001193125-25-280234.Report this figure71.0Diluted shares (weighted), Q1 FY2025, three months to 2025-03-3171,040,580 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-04, accession 0001193125-26-204047.Report this figure78.1Diluted shares (weighted), Q2 FY2025, three months to 2025-06-3078,126,257 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-03, accession 0001193125-26-330631.Report this figure99.0Diluted shares (weighted), Q3 FY2025, three months to 2025-09-3098,953,331 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-13, accession 0001193125-25-280234.Report this figure105Diluted shares (weighted), Q1 FY2026, three months to 2026-03-31105,472,766 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-04, accession 0001193125-26-204047.Report this figure108Diluted shares (weighted), Q2 FY2026, three months to 2026-06-30108,012,388 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-03, accession 0001193125-26-330631.Report this figure

Shares outstanding: 103.65mShares outstanding, period not labelled, at 2026-07-27103,652,656 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-03, accession 0001193125-26-330631.Report this figure at Jul 27, 2026, from the cover of the 10-Q filed Aug 3, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. Listed shows no prices and gives no investment advice.